There are major impediments to clinical application of Tissue Engineering in veterinary medicine, including regulatory restrictions, interpatient variation in matrix formation, cell viability of cultured tissues, as well as safety of tissue engineeredneotissues. For instance, adult progenitor cells selected for tissue engineering are also involved in oncogenesis and metastasis (1), and the growth factors used to induce matrix synthesis are also involved in tumorigenesis (2). Towards producing safe,engineered fibrocartilage neotissues, the consequences of using in vitro bioactive stimulants on adult mesenchymal cells must be understood. The objective of this study was to identify similarities in oncogene expression and pAKT in tissue engineered constructs as compared to a positive control canine synovial cell sarcoma (SCS). Oncogenes and pAKT which are over-expressed in human SCS were selected as preliminary study targets. We hypothesized that 1) Cell viability and expression of pAKT, TLE1, bcl-2anti-apoptotic protein, HER2/neu, MUC-1, and IGF-2 would be increased in growth factor treated synoviocyte pellets, versus serum treated pellets; and 2) Oncogene expression between cell pellets and SCS will be greater than native synovium tissue controls.
展开▼
